Global Primary Sclerosing Cholangitis Treatment Market Insights, Forecast to 2030

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Liver Transplantation Operation
1.2.3 UDCA Drugs
1.2.4 PSC Drugs
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis Treatment Market Perspective (2019-2030)
2.2 Global Primary Sclerosing Cholangitis Treatment Growth Trends by Region
2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Size by Region (2019-2024)
2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2025-2030)
2.3 Primary Sclerosing Cholangitis Treatment Market Dynamics
2.3.1 Primary Sclerosing Cholangitis Treatment Industry Trends
2.3.2 Primary Sclerosing Cholangitis Treatment Market Drivers
2.3.3 Primary Sclerosing Cholangitis Treatment Market Challenges
2.3.4 Primary Sclerosing Cholangitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Primary Sclerosing Cholangitis Treatment by Players
3.1.1 Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2019-2024)
3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Primary Sclerosing Cholangitis Treatment, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2023
3.5 Global Key Players of Primary Sclerosing Cholangitis Treatment Head office and Area Served
3.6 Global Key Players of Primary Sclerosing Cholangitis Treatment, Product and Application
3.7 Global Key Players of Primary Sclerosing Cholangitis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis Treatment Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2019-2024)
4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2025-2030)
5 Primary Sclerosing Cholangitis Treatment Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2019-2024)
5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
6.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Type
6.2.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
6.2.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
6.2.3 North America Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Application
6.3.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
6.3.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
6.3.3 North America Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
6.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Country
6.4.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
6.4.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type
7.2.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
7.2.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
7.2.3 Europe Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application
7.3.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
7.3.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
7.3.3 Europe Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
7.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country
7.4.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
7.4.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
8.2 China Primary Sclerosing Cholangitis Treatment Market Size by Type
8.2.1 China Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
8.2.2 China Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
8.2.3 China Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
8.3 China Primary Sclerosing Cholangitis Treatment Market Size by Application
8.3.1 China Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
8.3.2 China Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
8.3.3 China Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
9.2 Asia Primary Sclerosing Cholangitis Treatment Market Size by Type
9.2.1 Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
9.2.2 Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
9.2.3 Asia Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
9.3 Asia Primary Sclerosing Cholangitis Treatment Market Size by Application
9.3.1 Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
9.3.2 Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
9.3.3 Asia Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
9.4 Asia Primary Sclerosing Cholangitis Treatment Market Size by Region
9.4.1 Asia Primary Sclerosing Cholangitis Treatment Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Primary Sclerosing Cholangitis Treatment Market Size by Region (2019-2024)
9.4.3 Asia Primary Sclerosing Cholangitis Treatment Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Details
11.1.2 Allergan Business Overview
11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
11.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.1.5 Allergan Recent Developments
11.2 Glenmark
11.2.1 Glenmark Company Details
11.2.2 Glenmark Business Overview
11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
11.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.2.5 Glenmark Recent Developments
11.3 Impax Laboratories
11.3.1 Impax Laboratories Company Details
11.3.2 Impax Laboratories Business Overview
11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
11.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.3.5 Impax Laboratories Recent Developments
11.4 Mylan
11.4.1 Mylan Company Details
11.4.2 Mylan Business Overview
11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
11.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.4.5 Mylan Recent Developments
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Details
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.5.5 Teva Pharmaceuticals Recent Developments
11.6 Dr. Falk Pharma
11.6.1 Dr. Falk Pharma Company Details
11.6.2 Dr. Falk Pharma Business Overview
11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.6.5 Dr. Falk Pharma Recent Developments
11.7 Daewoong Pharmaceutical
11.7.1 Daewoong Pharmaceutical Company Details
11.7.2 Daewoong Pharmaceutical Business Overview
11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
11.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.7.5 Daewoong Pharmaceutical Recent Developments
11.8 Epic Pharma
11.8.1 Epic Pharma Company Details
11.8.2 Epic Pharma Business Overview
11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.8.5 Epic Pharma Recent Developments
11.9 Mitsubishi Tanabe Pharma
11.9.1 Mitsubishi Tanabe Pharma Company Details
11.9.2 Mitsubishi Tanabe Pharma Business Overview
11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.9.5 Mitsubishi Tanabe Pharma Recent Developments
11.10 Lannett
11.10.1 Lannett Company Details
11.10.2 Lannett Business Overview
11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
11.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.10.5 Lannett Recent Developments
11.11 Bruschettini
11.11.1 Bruschettini Company Details
11.11.2 Bruschettini Business Overview
11.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
11.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.11.5 Bruschettini Recent Developments
11.12 Shanghai Pharma
11.12.1 Shanghai Pharma Company Details
11.12.2 Shanghai Pharma Business Overview
11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.12.5 Shanghai Pharma Recent Developments
11.13 Grindeks
11.13.1 Grindeks Company Details
11.13.2 Grindeks Business Overview
11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
11.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.13.5 Grindeks Recent Developments
11.14 Acorda Therapeutics
11.14.1 Acorda Therapeutics Company Details
11.14.2 Acorda Therapeutics Business Overview
11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
11.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.14.5 Acorda Therapeutics Recent Developments
11.15 Gilead Sciences
11.15.1 Gilead Sciences Company Details
11.15.2 Gilead Sciences Business Overview
11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
11.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.15.5 Gilead Sciences Recent Developments
11.16 Intercept Pharmaceuticals
11.16.1 Intercept Pharmaceuticals Company Details
11.16.2 Intercept Pharmaceuticals Business Overview
11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.16.5 Intercept Pharmaceuticals Recent Developments
11.17 Shire Plc
11.17.1 Shire Plc Company Details
11.17.2 Shire Plc Business Overview
11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
11.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.17.5 Shire Plc Recent Developments
11.18 NGM Biopharmaceuticals
11.18.1 NGM Biopharmaceuticals Company Details
11.18.2 NGM Biopharmaceuticals Business Overview
11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.18.5 NGM Biopharmaceuticals Recent Developments
11.19 Conatus Pharmaceuticals
11.19.1 Conatus Pharmaceuticals Company Details
11.19.2 Conatus Pharmaceuticals Business Overview
11.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.19.5 Conatus Pharmaceuticals Recent Developments
11.20 Durect Corporation
11.20.1 Durect Corporation Company Details
11.20.2 Durect Corporation Business Overview
11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
11.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.20.5 Durect Corporation Recent Developments
11.21 Sirnaomics
11.21.1 Sirnaomics Company Details
11.21.2 Sirnaomics Business Overview
11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
11.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.21.5 Sirnaomics Recent Developments
11.22 Shenzhen HighTide Biopharmaceuticals
11.22.1 Shenzhen HighTide Biopharmaceuticals Company Details
11.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview
11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.22.5 Shenzhen HighTide Biopharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Liver Transplantation Operation
Table 3. Key Players of UDCA Drugs
Table 4. Key Players of PSC Drugs
Table 5. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Primary Sclerosing Cholangitis Treatment Market Share by Region (2019-2024)
Table 9. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Primary Sclerosing Cholangitis Treatment Market Share by Region (2025-2030)
Table 11. Primary Sclerosing Cholangitis Treatment Market Trends
Table 12. Primary Sclerosing Cholangitis Treatment Market Drivers
Table 13. Primary Sclerosing Cholangitis Treatment Market Challenges
Table 14. Primary Sclerosing Cholangitis Treatment Market Restraints
Table 15. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Players (2019-2024)
Table 17. Global Top Primary Sclerosing Cholangitis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2023)
Table 18. Global Primary Sclerosing Cholangitis Treatment Industry Ranking 2022 VS 2023 VS 2024
Table 19. Global 5 Largest Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 20. Global Key Players of Primary Sclerosing Cholangitis Treatment, Headquarters and Area Served
Table 21. Global Key Players of Primary Sclerosing Cholangitis Treatment, Product and Application
Table 22. Global Key Players of Primary Sclerosing Cholangitis Treatment, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2019-2024)
Table 26. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2025-2030)
Table 28. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Application (2019-2024)
Table 30. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Application (2025-2030)
Table 32. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 33. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
Table 34. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 35. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
Table 36. North America Primary Sclerosing Cholangitis Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 40. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
Table 41. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 42. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
Table 43. Europe Primary Sclerosing Cholangitis Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 45. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 46. China Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 47. China Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
Table 48. China Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 49. China Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
Table 50. Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 51. Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
Table 52. Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 53. Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
Table 54. Asia Primary Sclerosing Cholangitis Treatment Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 55. Asia Primary Sclerosing Cholangitis Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 56. Asia Primary Sclerosing Cholangitis Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 62. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 64. Allergan Company Details
Table 65. Allergan Business Overview
Table 66. Allergan Primary Sclerosing Cholangitis Treatment Product
Table 67. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 68. Allergan Recent Developments
Table 69. Glenmark Company Details
Table 70. Glenmark Business Overview
Table 71. Glenmark Primary Sclerosing Cholangitis Treatment Product
Table 72. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 73. Glenmark Recent Developments
Table 74. Impax Laboratories Company Details
Table 75. Impax Laboratories Business Overview
Table 76. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product
Table 77. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 78. Impax Laboratories Recent Developments
Table 79. Mylan Company Details
Table 80. Mylan Business Overview
Table 81. Mylan Primary Sclerosing Cholangitis Treatment Product
Table 82. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 83. Mylan Recent Developments
Table 84. Teva Pharmaceuticals Company Details
Table 85. Teva Pharmaceuticals Business Overview
Table 86. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 87. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 88. Teva Pharmaceuticals Recent Developments
Table 89. Dr. Falk Pharma Company Details
Table 90. Dr. Falk Pharma Business Overview
Table 91. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product
Table 92. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 93. Dr. Falk Pharma Recent Developments
Table 94. Daewoong Pharmaceutical Company Details
Table 95. Daewoong Pharmaceutical Business Overview
Table 96. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product
Table 97. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 98. Daewoong Pharmaceutical Recent Developments
Table 99. Epic Pharma Company Details
Table 100. Epic Pharma Business Overview
Table 101. Epic Pharma Primary Sclerosing Cholangitis Treatment Product
Table 102. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 103. Epic Pharma Recent Developments
Table 104. Mitsubishi Tanabe Pharma Company Details
Table 105. Mitsubishi Tanabe Pharma Business Overview
Table 106. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product
Table 107. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 108. Mitsubishi Tanabe Pharma Recent Developments
Table 109. Lannett Company Details
Table 110. Lannett Business Overview
Table 111. Lannett Primary Sclerosing Cholangitis Treatment Product
Table 112. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 113. Lannett Recent Developments
Table 114. Bruschettini Company Details
Table 115. Bruschettini Business Overview
Table 116. Bruschettini Primary Sclerosing Cholangitis Treatment Product
Table 117. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 118. Bruschettini Recent Developments
Table 119. Shanghai Pharma Company Details
Table 120. Shanghai Pharma Business Overview
Table 121. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product
Table 122. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 123. Shanghai Pharma Recent Developments
Table 124. Grindeks Company Details
Table 125. Grindeks Business Overview
Table 126. Grindeks Primary Sclerosing Cholangitis Treatment Product
Table 127. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 128. Grindeks Recent Developments
Table 129. Acorda Therapeutics Company Details
Table 130. Acorda Therapeutics Business Overview
Table 131. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product
Table 132. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 133. Acorda Therapeutics Recent Developments
Table 134. Gilead Sciences Company Details
Table 135. Gilead Sciences Business Overview
Table 136. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product
Table 137. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 138. Gilead Sciences Recent Developments
Table 139. Intercept Pharmaceuticals Company Details
Table 140. Intercept Pharmaceuticals Business Overview
Table 141. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 142. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 143. Intercept Pharmaceuticals Recent Developments
Table 144. Shire Plc Company Details
Table 145. Shire Plc Business Overview
Table 146. Shire Plc Primary Sclerosing Cholangitis Treatment Product
Table 147. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 148. Shire Plc Recent Developments
Table 149. NGM Biopharmaceuticals Company Details
Table 150. NGM Biopharmaceuticals Business Overview
Table 151. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 152. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 153. NGM Biopharmaceuticals Recent Developments
Table 154. Conatus Pharmaceuticals Company Details
Table 155. Conatus Pharmaceuticals Business Overview
Table 156. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 157. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 158. Conatus Pharmaceuticals Recent Developments
Table 159. Durect Corporation Company Details
Table 160. Durect Corporation Business Overview
Table 161. Durect Corporation Primary Sclerosing Cholangitis Treatment Product
Table 162. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 163. Durect Corporation Recent Developments
Table 164. Sirnaomics Company Details
Table 165. Sirnaomics Business Overview
Table 166. Sirnaomics Primary Sclerosing Cholangitis Treatment Product
Table 167. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 168. Sirnaomics Recent Developments
Table 169. Shenzhen HighTide Biopharmaceuticals Company Details
Table 170. Shenzhen HighTide Biopharmaceuticals Business Overview
Table 171. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 172. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
Table 173. Shenzhen HighTide Biopharmaceuticals Recent Developments
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Primary Sclerosing Cholangitis Treatment Market Share by Type: 2023 VS 2030
Figure 3. Liver Transplantation Operation Features
Figure 4. UDCA Drugs Features
Figure 5. PSC Drugs Features
Figure 6. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 7. Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2023 VS 2030
Figure 8. Hospital Case Studies
Figure 9. Clinics Case Studies
Figure 10. Other Case Studies
Figure 11. Primary Sclerosing Cholangitis Treatment Report Years Considered
Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Primary Sclerosing Cholangitis Treatment Market Share by Region: 2023 VS 2030
Figure 15. Global Primary Sclerosing Cholangitis Treatment Market Share by Players in 2023
Figure 16. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2023
Figure 18. North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
Figure 20. North America Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
Figure 21. North America Primary Sclerosing Cholangitis Treatment Market Share by Country (2019-2030)
Figure 22. United States Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Primary Sclerosing Cholangitis Treatment Market Size YoY (2019-2030) & (US$ Million)
Figure 25. Europe Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
Figure 26. Europe Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
Figure 27. Europe Primary Sclerosing Cholangitis Treatment Market Share by Country (2019-2030)
Figure 28. Germany Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. China Primary Sclerosing Cholangitis Treatment Market Size YoY (2019-2030) & (US$ Million)
Figure 35. China Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
Figure 36. China Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
Figure 37. Asia Primary Sclerosing Cholangitis Treatment Market Size YoY (2019-2030) & (US$ Million)
Figure 38. Asia Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
Figure 39. Asia Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
Figure 40. Asia Primary Sclerosing Cholangitis Treatment Market Share by Region (2019-2030)
Figure 41. Japan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. South Korea Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. China Taiwan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. India Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Australia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY (2019-2030) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
Figure 49. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
Figure 50. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Country (2019-2030)
Figure 51. Brazil Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Mexico Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Turkey Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Israel Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. GCC Countries Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 57. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 58. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 59. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 60. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 61. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 62. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 63. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 64. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 65. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 66. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 67. Bruschettini Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 68. Shanghai Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 69. Grindeks Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 70. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 71. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 72. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 73. Shire Plc Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 74. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 75. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 76. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 77. Sirnaomics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 78. Shenzhen HighTide Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit